Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Rheumatoid Arthritis, Systemic Juvenile 1Rectal Neoplasms 1Primary Myelofibrosis 1Periodic Fevers Syndrome 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Mevalonate Kinase Deficiency 1Metastatic Pancreatic Ductal Adenocarcinoma 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1Cryopyrin-Associated Periodic Syndromes 1Colorectal Neoplasms 1Colonic Neoplasms 1Clonal Cytopenia of Undetermined Significance 1Carcinoma, Renal Cell 1Carcinoma, Ductal 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1Arthritis, Juvenile 1Arthralgia 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

trametinib 1talimogene laherparepvec 1spartalizumab 1pembrolizumab 1nazartinib 1exemestane 1canakinumab 1Telomerase 1Tamoxifen 1Surgical Procedures, Operative 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Pemetrexed 1Paclitaxel 1Mastectomy, Subcutaneous 1Mastectomy, Segmental 1Mammaplasty 1Letrozole 1Indocyanine Green 1Doxorubicin 1Docetaxel 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Ductal × canakinumab × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔